Testing for hereditary mutations is increasingly recommended for people with cancer, but recommendations do not always translate into access to testing and appropriate counseling.

by Kate Yandell

Scientists and physicians discussed advances in targeted therapies and immunotherapies, as well as the lessons COVID-19 research has taught to cancer researchers.

by Kevin McLaughlin

Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.

by Anna Goshua

A study shows that a blood test for gastrointestinal tumor mutations gave results in a third of the time needed for solid tissue testing. Patients who received the blood test were more likely to enroll in clinical trials.

by Emma Yasinski

The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.

by Anna Azvolinsky

For a small group of pancreatic cancer patients who were able to receive therapies targeting the molecular alterations in their tumors, these matched therapies were associated with longer life.

by Cheryl Platzman Weinstock

Multigene panels that rely on next-generation sequencing are increasingly used to test for hereditary cancer risk-related mutations. The federal government aims to expand Medicare coverage for these tests.

by Ashley P. Taylor

Medical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.

by Anna Azvolinsky

Many cancer patients who received genomic testing of their cancers in a clinical trial did not fully understand the purpose of the testing.

by Emma Yasinski

Medical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.

by Anna Azvolinsky